Sarcoma

Official Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Study Purpose: To compare the progression free survival (PFS)  and the overall survival (OS)of olaparib plus temozolomide (Arm 1) as compared to investigator’s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uterine leiomyosarcoma who have received two or more prior lines of therapy as determined by investigator (local site) assessment.

Status: Recruiting

Official Title: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma  

Study Purpose: Is the combination of palbociclib plus cemiplimab better than palbociclib alone in the treatment of advanced dedifferentiated liposarcoma that cannot be removed by surgery

Status: Suspended

Official Title: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS  

Study Purpose: The purpose of this part of the research study is to evaluate how CGT9486 plus sunitinib affects GIST compared to just treatment with sunitinib alone.  

Status: Recruiting

Official Title: A Randomized, Double Blind, Placebo controlled, Phase 2 Study of INBRX 109 as Any line Therapy in Conventional Chondrosarcoma

Study Purpose: To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat population as measured by progression free survival assessed by central independent radiology review comparing INBRX-109 and placebo.

Status: Recruiting